{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T19:51:24Z","timestamp":1719172284202},"reference-count":10,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2009,10,27]],"date-time":"2009-10-27T00:00:00Z","timestamp":1256601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmazie in unserer Zeit"],"published-print":{"date-parts":[[2009,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Insgesamt ist die Auswahl an Wirkstoffen zur Behandlung der Afrikanischen Schlafkrankheit begrenzt. Die meisten Substanzen wurden bereits in der ersten H\u00e4lfte des vorigen Jahrhunderts eingef\u00fchrt. Unter Anwendung der heute g\u00fcltigen Regeln, w\u00e4re wohl keine davon entwickelt, geschweige denn zugelassen worden. Nebenwirkungen und (im Fall des Melarsoprols) Resistenz sind die gr\u00f6\u00dften Probleme dieser Substanzen. Eine neuere Entwicklung ist die Kombination von Eflornithin mit Nifurtimox, die in ersten klinischen Tests im Sp\u00e4tstadium der Infektion mit <jats:italic>T. brucei gambiense<\/jats:italic> anderen Kombinationen \u00fcberlegen war. F\u00fcr die Therapie des Sp\u00e4tstadiums der Infektion mit <jats:italic>T. brucei rhodesiense<\/jats:italic> bleibt aber weiterhin nur das Melarsoprol mit all seinen Problemen.<\/jats:p><jats:p>Nur eine neue Substanz (Parfuramidin), die zumindest theoretisch eine Kreuzresistenz mit Melarsoprol aufweisen k\u00f6nnte, ist in der klinischen Entwicklung. Ihr weiteres Schicksal ist momentan ungewiss. Zahlreiche biologische <jats:italic>Targets<\/jats:italic> und entsprechende Hemmstoffe sind beschrieben, es steht allerdings nicht zu erwarten, dass diese Entwicklungen kurzfristig zu neuen Therapien f\u00fchren werden.<\/jats:p>","DOI":"10.1002\/pauz.200900344","type":"journal-article","created":{"date-parts":[[2009,10,27]],"date-time":"2009-10-27T17:52:21Z","timestamp":1256665941000},"page":"552-558","source":"Crossref","is-referenced-by-count":4,"title":["Wirkstoffe zur Behandlung der Afrikanischen Schlafkrankheit. Im letzten Jahrhundert entwickelt"],"prefix":"10.1002","volume":"38","author":[{"given":"Martin","family":"Schlitzer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,10,27]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707354"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2007.02.004"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.2174\/138161207780162809"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pt.2008.04.006"},{"key":"e_1_2_1_6_2","first-page":"147","article-title":"Diamidines as antitrypanosomal, antileishmanial and antimalarial agents.","volume":"7","author":"Werbovetz V.","year":"2006","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00642-07"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0021-9258(18)48472-4","article-title":"Mechanism of the Irreversible Inactivation of Mouse Ornithine Decarboxylase by \u03b1\u2010Difluoromethylornithine.","volume":"267","author":"Poulin R.","year":"1992","journal-title":"J. Biol. Chem."},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01360-06"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0711014105"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pctr.0010039"}],"container-title":["Pharmazie in unserer Zeit"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpauz.200900344","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpauz.200900344","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pauz.200900344","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T19:15:15Z","timestamp":1699989315000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pauz.200900344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10,27]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["10.1002\/pauz.200900344"],"URL":"https:\/\/doi.org\/10.1002\/pauz.200900344","archive":["Portico"],"relation":{},"ISSN":["0048-3664","1615-1003"],"issn-type":[{"value":"0048-3664","type":"print"},{"value":"1615-1003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,27]]}}}